Phenotypes associated with this allele

• Allele Symbol: Tg(CAG-cre/Esr1*)1Lbe
• Allele Name: transgene insertion 1, Corrinne Lobe
• Allele ID: MGI:2677720
• Summary: 9 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Prkcsh^tm1Som/Prkcsh^tm1Som Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:5442315
cn2	Sec63^tm1Som/Sec63^tm1Som Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:5442324
cn3	Memo1^tm1.1Neh/Memo1^tm1.1Neh Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:5559031
cn4	Shank3^tm5.1Gfng/Shank3^tm5.1Gfng Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * C57BL/6J	MGI:5776355
cn5	Flcn^tm1Baba/Flcn^tm1.1Lss Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129S1/Sv * 129X1/SvJ	MGI:5445163
cn6	Vhl^tm1Lss/Vhl^tm1.1Lss Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129S1/Sv * 129X1/SvJ	MGI:3653510
cn7	Sirpa^tm1Umri/Sirpa^tm1Umri Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:5558023
cn8	Chat^tm1Jrs/Chat^tm1Jrs Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3046100
cn9	Chat^tm1Jrs/Chat^tm1Jrs Tg(CAG-cre/Esr1*)1Lbe/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	MGI:3707430

Genotype
MGI:5442315

cn1

• Allelic Composition: Prkcsh^tm1Som/Prkcsh^tm1Som; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:188763 )

• in mice treated with a high does tamoxifen induction regime

liver/biliary system

liver cyst ( J:188763 )

• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice

• severe by 4 to 5 months in tamoxifen-treated mice

• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype

• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype

growth/size/body

liver cyst ( J:188763 )

• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice

• severe by 4 to 5 months in tamoxifen-treated mice

• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype

• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
polycystic liver disease		DOID:0050770		J:188763

Genotype
MGI:5442324

cn2

• Allelic Composition: Sec63^tm1Som/Sec63^tm1Som; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

premature death ( J:188763 )

• in mice treated with a high does tamoxifen induction regime

liver/biliary system

liver cyst ( J:188763 )

• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice

• severe by 4 to 5 months in tamoxifen-treated mice

• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype

• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype

growth/size/body

liver cyst ( J:188763 )

• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice

• severe by 4 to 5 months in tamoxifen-treated mice

• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype

• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype

Genotype
MGI:5559031

cn3

• Allelic Composition: Memo1^tm1.1Neh/Memo1^tm1.1Neh; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

mortality/aging

premature death ( J:206626 )

• in tamoxifen-treated mice

reproductive system

azoospermia ( J:206626 )

♂ • in tamoxifen-treated mice

abnormal sex gland morphology ( J:206626 )

• small gonads in some litters of tamoxifen-treated mice

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:206626 )

N • fasted and fed tamoxifen-treated mice exhibit normal glucose and phosphate serum levels

increased circulating parathyroid hormone level ( J:206626 )

• in tamoxifen-treated mice

increased circulating calcium level ( J:206626 )

• in tamoxifen-treated mice

improved glucose tolerance ( J:206626 )

• tamoxifen-treated mice exhibit increased capacity for glucose disposal compared with control mice

increased insulin sensitivity ( J:206626 )

• tamoxifen-treated mice exhibit increased hypoglycemic response to exogenous insulin compared with control mice

increased vitamin D level ( J:206626 )

• elevated 1,25(OH)2D in tamoxifen-treated mice

growth/size/body

decreased body size ( J:206626 )

• in tamoxifen-treated mice

decreased body weight ( J:206626 )

• in tamoxifen-treated mice

weight loss ( J:206626 )

• in tamoxifen-treated mice

integument

decreased subcutaneous adipose tissue amount ( J:206626 )

• in tamoxifen-treated mice

abnormal coat/hair pigmentation ( J:206626 )

• greying hair in tamoxifen-treated mice

alopecia ( J:206626 )

• in tamoxifen-treated mice

adipose tissue

decreased subcutaneous adipose tissue amount ( J:206626 )

• in tamoxifen-treated mice

decreased white adipose tissue amount ( J:206626 )

• in tamoxifen-treated mice

skeleton

kyphosis ( J:206626 )

• in tamoxifen-treated mice

behavior/neurological

abnormal reflex ( J:206626 )

• abnormal hindlimb reflex in tamoxifen-treated mice

pigmentation

abnormal coat/hair pigmentation ( J:206626 )

• greying hair in tamoxifen-treated mice

endocrine/exocrine glands

abnormal sex gland morphology ( J:206626 )

• small gonads in some litters of tamoxifen-treated mice

cellular

azoospermia ( J:206626 )

♂ • in tamoxifen-treated mice

Genotype
MGI:5776355

cn4

• Allelic Composition: Shank3^tm5.1Gfng/Shank3^tm5.1Gfng; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * C57BL/6J

behavior/neurological

decreased exploration in new environment ( J:229668 )

• prior to tamoxifen administration, mice exhibit decreased total distance travelled in open field test as compared to controls

• following tamoxifen administration, phenotype is unchanged

increased anxiety-related response ( J:229668 )

• prior to tamoxifen administration, mice spend less time in open arm during elevated zero maze test as compared to controls

• following tamoxifen administration at P20-21, mice exhibit reduced anxiety in the maze test

• tamoxifen administration in adult mice results in an unchanged phenotype

increased grooming behavior ( J:229668 )

• prior to tamoxifen administration, mice exhibit repetitive grooming

• following tamoxifen administration, grooming is similar to control

impaired coordination ( J:229668 )

• prior to tamoxifen administration, mice exhibit decreased latency to fall in rotarod test as compared to controls

• following tamoxifen administration at P20-21, mice perform significantly better on rotarod

• tamoxifen administration in adult mice results in an unchanged phenotype

decreased vertical activity ( J:229668 )

• prior to tamoxifen administration, mice exhibit reduced rearing time and frequency as compared to controls

• following tamoxifen administration, phenotype is unchanged

abnormal social investigation ( J:229668 )

• prior to tamoxifen administration, mice exhibit no preference for a stranger mouse or novel object in a test of voluntary social interaction

• following tamoxifen administration, mice exhibit a preference for a stranger mouse over a novel object in a test of voluntary social interaction

growth/size/body

decreased body weight ( J:229668 )

• as compared to wild-type mice (no tamoxifen administered)

nervous system

abnormal medium spiny neuron morphology ( J:229668 )

• prior to tamoxifen administration, mice exhibit a reduction of spine density in medium spiny neurons as compared to controls

• following tamoxifen administration, spine density is increased to a greater density than controls

abnormal dendritic spine morphology ( J:229668 )

• prior to tamoxifen administration, mice exhibit a reduction of spine density in medium spiny neurons

• following tamoxifen administration, spine density is increased to a greater density than controls

decreased excitatory postsynaptic current amplitude ( J:229668 )

• prior to tamoxifen administration, mice exhibit a reduced field population spikes in the dorsal striatum as compared to controls

• following tamoxifen administration, mice exhibit field responses similar to control

abnormal miniature excitatory postsynaptic currents ( J:229668 )

• prior to tamoxifen administration, mice exhibit a reduced mEPSC frequency as compared to controls

• following tamoxifen administration, mice exhibit mEPSC frequencies similar to control

Genotype
MGI:5445163

cn5

• Allelic Composition: Flcn^tm1Baba/Flcn^tm1.1Lss; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

immune system

arrested B cell differentiation ( J:189078 )

• pro-B cell block in the bone marrow following tamoxifen-treatment

decreased B cell number ( J:189078 )

• CD19+ cells in the spleen following tamoxifen-treatment

renal/urinary system

kidney cyst ( J:189078 )

• in tamoxifen-treated mice

• in tamoxifen-treated mice however, kidney phenotype is rescued by rapamycin treatment

kidney failure ( J:189078 )

• in tamoxifen-treated mice

• however, kidney phenotype is rescued by rapamycin treatment

hematopoietic system

arrested B cell differentiation ( J:189078 )

• pro-B cell block in the bone marrow following tamoxifen-treatment

decreased B cell number ( J:189078 )

• CD19+ cells in the spleen following tamoxifen-treatment

growth/size/body

kidney cyst ( J:189078 )

• in tamoxifen-treated mice

• in tamoxifen-treated mice however, kidney phenotype is rescued by rapamycin treatment

Genotype
MGI:3653510

cn6

• Allelic Composition: Vhl^tm1Lss/Vhl^tm1.1Lss; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

mortality/aging

lethality throughout fetal growth and development, complete penetrance ( J:110518 )

• all embryos of pregnant females injected with 2 mg of tamoxifen at E10.5 to inactive Vhlh during mid-gestational stage, die between E14.5 and E15.5

growth/size/body

decreased embryo size ( J:110518 )

• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls

cardiovascular system

abnormal blood vessel morphology ( J:110518 )

• treatment of pregnant females at E10.5 with tamoxifen results in abnormal vasculature and dilated blood vessels in the body of E14.7 embryos

abnormal placental labyrinth vasculature morphology ( J:110518 )

• dilated vessels are frequently seen after tamoxifen treatment

abnormal vitelline vasculature morphology ( J:110518 )

• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos

hemorrhage ( J:110518 )

• treatment of pregnant females at E10.5 with tamoxifen results in hemorrhage in the dorsolateral region of embryos at E14.5

cellular

decreased renal tubule apoptosis ( J:155367 )

• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice

embryo

abnormal vitelline vasculature morphology ( J:110518 )

• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos

decreased embryo size ( J:110518 )

• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls

embryo tissue necrosis ( J:110518 )

• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis

abnormal placenta labyrinth morphology ( J:110518 )

• when pregnant females are injected with tamoxifen at E10.5, frequently observe dilated blood vessels and spongiotriophoblast cells in the labyrinthine layer

abnormal placental labyrinth vasculature morphology ( J:110518 )

• dilated vessels are frequently seen after tamoxifen treatment

thin placenta labyrinth ( J:110518 )

• thickness of the labyrinthine layer is reduced when pregnant females are injected with tamoxifen at E10.5

liver/biliary system

focal hepatic necrosis ( J:110518 )

• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos

integument

pallor ( J:110518 )

• seen in embryos of pregnant females injected with tamoxifen at E10.5

homeostasis/metabolism

decreased circulating creatinine level ( J:155367 )

• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly lower serum creatinine levels than tamoxifen-treated control mice (0.24 +/- 0.04 mg/dl versus 0.72 +/- 0.16 mg/dL, respectively)

decreased blood urea nitrogen level ( J:155367 )

• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice exhibit significantly lower serum BUN levels than tamoxifen-treated control mice (52.12 +/- 6.61 mg/dl versus 138.10 +/- 13.03 mg/dL, respectively)

decreased susceptibility to kidney reperfusion injury ( J:155367 )

• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration

renal/urinary system

decreased renal tubule apoptosis ( J:155367 )

• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice

decreased susceptibility to kidney reperfusion injury ( J:155367 )

• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration

Genotype
MGI:5558023

cn7

• Allelic Composition: Sirpa^tm1Umri/Sirpa^tm1Umri; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

nervous system

abnormal synapse morphology ( J:204011 )

• as determined by VGLUT1 (Slc17a7) staining, mice treated with tamoxifen at P15 exhibit impaired maturation of presynaptic terminals compared with control mice

• however, mice treated tamoxifen at P0 exhibit normal initial synapse development and mice treated at P30 exhibit normal synapse maintenance

abnormal synaptic vesicle morphology ( J:204011 )

• irregular shape in tamoxifen-treated mice

abnormal synaptic vesicle number ( J:204011 )

• tamoxifen treated mice exhibit fewer synaptic vesicles and fewer docked synaptic vesicles in asymmetric synapses compared with control mice

abnormal excitatory postsynaptic potential ( J:204011 )

• strongly diminished Input-output curves of field excitatory postsynaptic potential slope in tamoxifen-treated mice

• however, fiber volley amplitude is normal

reduced long-term potentiation ( J:204011 )

• in tamoxifen-treated mice

enhanced paired-pulse facilitation ( J:204011 )

• in tamoxifen-treated mice

Genotype
MGI:3046100

cn8

• Allelic Composition: Chat^tm1Jrs/Chat^tm1Jrs; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

postnatal lethality, complete penetrance ( J:89596 )

• mutant mice die by P14 - P15 following treatment with 100 ug of tamoxifen on P0 which results in excision of the floxed sequence in greater than 50% of motor neurons

nervous system

abnormal innervation pattern to muscle ( J:89596 )

• following a low dose of tamoxifen (5 ug) on P0, which results in excision of the floxed sequence in 10-20% of motor neurons, an increase in doubly innervated neuromuscular junctions is seen

• in these doubly innervated neuromuscular junctions when a non-excised axon is present it is significantly larger than the excised axon

behavior/neurological

weakness ( J:89596 )

• mutant mice become noticeably weak by P9 following treatment with 100 ug of tamoxifen on P0

Genotype
MGI:3707430

cn9

• Allelic Composition: Chat^tm1Jrs/Chat^tm1Jrs; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL

mortality/aging

postnatal lethality, complete penetrance ( J:89596 )

• when receiving a high dose of tamoxifen at P0, mice display weakness at P9 and die at P14-15

nervous system

abnormal axon morphology ( J:89596 )

• at synapses innervated by a Chat +ve and a Chat -ve axons, the pre-terminal caliber of the Chat +ve axon is usually greater and never less than the Chat -ve diameter; average axon diameter at synapses with two Chat -ve or 2 Chat +ve axons are similar

• at synapses innervated by 2 Chat +ve axons, average diameter is less than the Chat +ve axon innervating a synapse also innervated by a Chat -ve axon; average diameter of axons at Chat -ve dually innervated synapses is greater than diameter of Chat -ve axon at a synapse also innervated by a Chat +ve axon

• these results suggest that activity differences between axons (Chat +ve - active, normal vs Chat -ve - inactive) determine size of axon branches at NMJs

abnormal neuromuscular synapse morphology ( J:89596 )

• at NMJs that are doubly innervated by 1 Chat +ve and 1 Chat -ve axon, the Chat-positive axon occupies more than half of the total area occupied by both axons together (~85%); this is the case with both high and low doses of tamoxifen

• in high dose tamoxifen NMJs, this pattern is observed even though the majority of axons are Chat -ve, indicating that the greater area occupied by Chat +ve axons is not the result of a bias of higher Chat +ve axon numbers

• in NMJs innervated singly or doubly by Chat -ve axons, the axons fully occupy the synaptic sites, indicating that Chat -ve axons do not withdraw from synapses

behavior/neurological

weakness ( J:89596 )

• after a high dose of tamoxifen administered after birth (P0), mice become noticeably weaker than nontransgenic littermates